Literature DB >> 16290004

Stimulation of hepatic phenylalanine hydroxylase activity but not Pah-mRNA expression upon oral loading of tetrahydrobiopterin in normal mice.

Rossana Scavelli1, Zhaobing Ding, Nenad Blau, Jan Haavik, Aurora Martínez, Beat Thöny.   

Abstract

Tetrahydrobiopterin (BH4) supplementation in patients with BH4-responsive phenylalanine hydroxylase (PAH) deficiency is an alternative to low-phenylalanine diet. To further investigate hepatic BH4-responsiveness, oral administration of 50 mg BH4/kg/day for 5 weeks was performed in wild-type mice. We observed a 2-fold increase in PAH protein by quantitative Western blot analysis and a 1.7-fold increase in enzyme activity, but no change in Pah-mRNA expression by quantitative real-time PCR analysis in treated mice compared to controls. Our findings support the proposed chemical-chaperone effect of BH4 to protect PAH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16290004     DOI: 10.1016/j.ymgme.2005.09.015

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  10 in total

1.  Chaperone-like therapy with tetrahydrobiopterin in clinical trials for phenylketonuria: is genotype a predictor of response?

Authors:  Christineh N Sarkissian; Alejandra Gamez; Patrick Scott; Jerome Dauvillier; Alejandro Dorenbaum; Charles R Scriver; Raymond C Stevens
Journal:  JIMD Rep       Date:  2011-12-06

Review 2.  Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators.

Authors:  Ania C Muntau; João Leandro; Michael Staudigl; Felix Mayer; Søren W Gersting
Journal:  J Inherit Metab Dis       Date:  2014-04-01       Impact factor: 4.982

Review 3.  Phenylketonuria as a model for protein misfolding diseases and for the development of next generation orphan drugs for patients with inborn errors of metabolism.

Authors:  Ania C Muntau; Søren W Gersting
Journal:  J Inherit Metab Dis       Date:  2010-09-08       Impact factor: 4.982

4.  Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases.

Authors:  Angel L Pey; Francois Stricher; Luis Serrano; Aurora Martinez
Journal:  Am J Hum Genet       Date:  2007-10-02       Impact factor: 11.025

Review 5.  Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines.

Authors:  A Nakashima; N Hayashi; Y S Kaneko; K Mori; E L Sabban; Toshiharu Nagatsu; A Ota
Journal:  J Neural Transm (Vienna)       Date:  2009-04-25       Impact factor: 3.575

6.  Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria.

Authors:  Angel L Pey; Ming Ying; Nunilo Cremades; Adrian Velazquez-Campoy; Tanja Scherer; Beat Thöny; Javier Sancho; Aurora Martinez
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

7.  Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system.

Authors:  Zhaobing Ding; Cary O Harding; Alexandre Rebuffat; Lina Elzaouk; Jon A Wolff; Beat Thöny
Journal:  Mol Ther       Date:  2008-03-11       Impact factor: 11.454

8.  Biochemical characterization of mutant phenylalanine hydroxylase enzymes and correlation with clinical presentation in hyperphenylalaninaemic patients.

Authors:  S F Dobrowolski; A L Pey; R Koch; H Levy; C C Ellingson; E W Naylor; A Martinez
Journal:  J Inherit Metab Dis       Date:  2008-10-21       Impact factor: 4.982

9.  Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria.

Authors:  Alexandre Rebuffat; Cary O Harding; Zhaobing Ding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

10.  A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria.

Authors:  Helene J Bustad; Karen Toska; Caroline Schmitt; Marta Vorland; Lars Skjærven; Juha P Kallio; Sylvie Simonin; Philippe Letteron; Jarl Underhaug; Sverre Sandberg; Aurora Martinez
Journal:  Mol Ther       Date:  2019-12-04       Impact factor: 11.454

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.